NCT03376958View on ClinicalTrials.gov

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

February 1, 2019

Study Completion Date

April 30, 2019

Conditions
Relapsed and RefractoryDiffuse Large B Cell Lymphoma
Interventions
DRUG

Apatinib

Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.

Trial Locations (1)

450052

Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Zhengzhou University

OTHER

NCT03376958 - Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | Biotech Hunter | Biotech Hunter